Increasingly, pharmaceutical companies are recognizing the efficiencies and cost benefits of long-term outsourcing of functional services, particularly non-core competencies. The strategic-partner agreement between Eli Lilly and i3 Statprobe announced in August 2008 builds on our steady growth in functional service alliances over the past 10 years.

A functional alliance with i3 Statprobe goes beyond typical study-by-study data services outsourcing. We draw on a set of unique tools and experiences to create a team that is tailored exclusively to the client’s business goals. This customer-focused team can handle a single function across several drug programs, a range of functions within a single therapeutic area, or any other defined need—serving as a consistent, scalable resource.

This new trend toward full-capacity strategic partnerships suggests a major shift in sponsor-CRO relationships. i3 Statprobe has the experience and expertise necessary to be a trusted collaborative partner. We offer proven processes, built-in quality mechanisms, and an in-depth understanding of critical success factors. i3 Statprobe provides expert professionals including medical writers, statistical programmers, biostatisticians, data management associates, and project managers. i3’s IT specialists also work closely with the customer to facilitate information exchanges between systems, and applies its experience gained through similar engagements to offer creative solutions to joint technology challenges.

In addition to our therapeutic and operational expertise, we believe it is imperative to be a flexible, scalable organization that can precisely align with and support our client’s needs at each stage of the development continuum. The range and combinations of services, systems, and staffing models we offer demonstrate that providing customizable solutions is our specialty.

Learn more...
IN THE CENTERWATCH REPORT ON OUTSOURCING

ABOUT i3 STATPROBE STRATEGIC ALLIANCES

Strategic alliances provide a “win-win” to support the objectives of both organizations. Successful implementation of risk-reduction and cost-reduction mechanisms benefits the alliance. Quality is delivered by the consistent improvement of workflow processes and dedicated teams. Our clients value our experience as we seek the best solutions for their unique needs and challenges. This new model in strategic partnerships results in more efficient drug development, with increased quality, speed, and productivity.

For more information on partnering with i3 Statprobe, contact us today.